{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:56Z","timestamp":1790716856900,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,6,15]]},"DOI":"10.1038\/onc.2016.494","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T18:43:57Z","timestamp":1485197037000},"page":"3441-3449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment"],"prefix":"10.1038","volume":"36","author":[{"given":"A","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Chiosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y L","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"BFonc2016494_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265\u2013276.","journal-title":"Blood"},{"key":"BFonc2016494_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804\u2013815.","journal-title":"N Engl J Med"},{"key":"BFonc2016494_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24282","volume":"91","author":"KR Rai","year":"2016","unstructured":"Rai KR, Jain P . Chronic lymphocytic leukemia (CLL)-then and now. Am J Hematol 2016; 91: 330\u2013340.","journal-title":"Am J Hematol"},{"key":"BFonc2016494_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32\u201342.","journal-title":"N Engl J Med"},{"key":"BFonc2016494_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997\u20131007.","journal-title":"N Engl J Med"},{"key":"BFonc2016494_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88\u201394.","journal-title":"J Clin Oncol"},{"key":"BFonc2016494_CR7","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","volume":"125","author":"J Sharman","year":"2015","unstructured":"Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 2015; 125: 2336\u20132343.","journal-title":"Blood"},{"key":"BFonc2016494_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714\u2013726.","journal-title":"Cell"},{"key":"BFonc2016494_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525\u2013530.","journal-title":"Nature"},{"key":"BFonc2016494_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526: 519\u2013524.","journal-title":"Nature"},{"key":"BFonc2016494_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.chembiol.2015.12.006","volume":"23","author":"L Shrestha","year":"2016","unstructured":"Shrestha L, Patel HJ, Chiosis G . Chemical tools to investigate mechanisms associated with HSP90 and HSP70 in disease. Cell Chem Biol 2016; 23: 158\u2013172.","journal-title":"Cell Chem Biol"},{"key":"BFonc2016494_CR12","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1158\/1078-0432.CCR-11-2138","volume":"18","author":"M Scaltriti","year":"2012","unstructured":"Scaltriti M, Dawood S, Cortes J . Molecular pathways: targeting hsp90\u2013who benefits and who does not. Clin Cancer Res 2012; 18: 4508\u20134513.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016494_CR13","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2008-02-139139","volume":"112","author":"L Trentin","year":"2008","unstructured":"Trentin L, Frasson M, Donella-Deana A, Frezzato F, Pagano MA, Tibaldi E et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008; 112: 4665\u20134674.","journal-title":"Blood"},{"key":"BFonc2016494_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2010-01-263756","volume":"116","author":"E Hertlein","year":"2010","unstructured":"Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010; 116: 45\u201353.","journal-title":"Blood"},{"key":"BFonc2016494_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.18632\/oncotarget.491","volume":"3","author":"E Walsby","year":"2012","unstructured":"Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C . The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 2012; 3: 525\u2013534.","journal-title":"Oncotarget"},{"key":"BFonc2016494_CR16","doi-asserted-by":"publisher","first-page":"abstr 2537","DOI":"10.1200\/jco.2015.33.15_suppl.2537","volume":"33","author":"J Gerecitano","year":"2015","unstructured":"Gerecitano J, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM et al. Phase I trial of the HSP-90 inhibitor PU-H71. J Clin Oncol 2015; 33: abstr 2537.","journal-title":"J Clin Oncol"},{"key":"BFonc2016494_CR17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nchembio.670","volume":"7","author":"K Moulick","year":"2011","unstructured":"Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011; 7: 818\u2013826.","journal-title":"Nat Chem Biol"},{"key":"BFonc2016494_CR18","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.celrep.2015.10.073","volume":"13","author":"H Zong","year":"2015","unstructured":"Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S et al. A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. Cell Rep 2015; 13: 2159\u20132173.","journal-title":"Cell Rep"},{"key":"BFonc2016494_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2014.09.001","volume":"35","author":"T Taldone","year":"2014","unstructured":"Taldone T, Ochiana SO, Patel PD, Chiosis G . Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci 2014; 35: 592\u2013603.","journal-title":"Trends Pharmacol Sci"},{"key":"BFonc2016494_CR20","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1172\/JCI80714","volume":"125","author":"RL Goldstein","year":"2015","unstructured":"Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest 2015; 125: 4559\u20134571.","journal-title":"J Clin Invest"},{"key":"BFonc2016494_CR21","first-page":"456","volume":"10","author":"LE Robertson","year":"1996","unstructured":"Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ . Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456\u2013459.","journal-title":"Leukemia"},{"key":"BFonc2016494_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","volume":"113","author":"K Balakrishnan","year":"2009","unstructured":"Balakrishnan K, Burger JA, Wierda WG, Gandhi V . AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113: 149\u2013153.","journal-title":"Blood"},{"key":"BFonc2016494_CR23","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379\u20133389.","journal-title":"Blood"},{"key":"BFonc2016494_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ejca.2009.11.023","volume":"46","author":"O Grzybowska-Izydorczyk","year":"2010","unstructured":"Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P . Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010; 46: 800\u2013810.","journal-title":"Eur J Cancer"},{"key":"BFonc2016494_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/10428194.2011.610014","volume":"53","author":"RE Hayden","year":"2012","unstructured":"Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM . Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk Lymphoma 2012; 53: 537\u2013549.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2016494_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","volume":"2011","author":"JA Burger","year":"2011","unstructured":"Burger JA . Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2011; 2011: 96\u2013103.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"BFonc2016494_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nchembio.1368","volume":"9","author":"OS Andersen","year":"2013","unstructured":"Andersen OS . Membrane proteins: through thick and thin. Nat Chem Biol 2013; 9: 667\u2013668.","journal-title":"Nat Chem Biol"},{"key":"BFonc2016494_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/leu.2014.263","volume":"29","author":"S Cheng","year":"2015","unstructured":"Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL . Functional characterization of BTK mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 2015; 29: 895\u2013900.","journal-title":"Leukemia"},{"key":"BFonc2016494_CR29","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.18632\/oncotarget.6727","volume":"7","author":"A Guo","year":"2015","unstructured":"Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 2015; 7: 4598\u20134610.","journal-title":"Oncotarget"},{"key":"BFonc2016494_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014; 28: 649\u2013657.","journal-title":"Leukemia"},{"key":"BFonc2016494_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88\u201392.","journal-title":"Nature"},{"key":"BFonc2016494_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"M Duhren-von Minden","year":"2012","unstructured":"Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309\u2013312.","journal-title":"Nature"},{"key":"BFonc2016494_CR33","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014; 370: 2352\u20132354.","journal-title":"N Engl J Med"},{"key":"BFonc2016494_CR34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286\u20132294.","journal-title":"N Engl J Med"},{"key":"BFonc2016494_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"TM Liu","year":"2015","unstructured":"Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 2015; 126: 61\u201368.","journal-title":"Blood"},{"key":"BFonc2016494_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-09-1519","volume":"16","author":"Z Song","year":"2010","unstructured":"Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L et al. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 2010; 16: 587\u2013599.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016494_CR37","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00277-016-2788-6","volume":"95","author":"A Haerzschel","year":"2016","unstructured":"Haerzschel A, Catusse J, Hutterer E, Paunovic M, Zirlik K, Eibel H et al. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. Ann Hematol. 2016; 95: 1979\u20131988.","journal-title":"Ann Hematol."},{"key":"BFonc2016494_CR38","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/leu.2008.163","volume":"22","author":"C Yang","year":"2008","unstructured":"Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008; 22: 1755\u20131766.","journal-title":"Leukemia"},{"key":"BFonc2016494_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/leu.2008.304","volume":"23","author":"P Lu","year":"2009","unstructured":"Lu P, Yang C, Guasparri I, Harrington W, Wang YL, Cesarman E . Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. Leukemia 2009; 23: 807\u2013810.","journal-title":"Leukemia"},{"key":"BFonc2016494_CR40","doi-asserted-by":"crossref","first-page":"43881","DOI":"10.18632\/oncotarget.6316","volume":"6","author":"J Ma","year":"2015","unstructured":"Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A et al. Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget 2015; 6: 43881\u201343896.","journal-title":"Oncotarget"},{"key":"BFonc2016494_CR41","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","volume":"118","author":"S Cheng","year":"2011","unstructured":"Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011; 118: 6342\u20136352.","journal-title":"Blood"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2016494","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2016.494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:13:09Z","timestamp":1647893589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,6,15]]}},"alternative-id":["BFonc2016494"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.494","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]},"assertion":[{"value":"8 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Memorial Sloan-Kettering Cancer Center holds the intellectual rights to PU-H71 (GC). Samus Therapeutics, of which GC has partial ownership, has licensed PU-H71. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}